January 21, 2025

Only 2% of Eligible Patients Get New Obesity Drug

"These findings suggest that inequities persist in medication access in this understudied subgroup."

Conexiant

January 21, 2025

Pediatric Obesity Treatment Success Predicts Adult Outcomes

A study of over 6,700 pediatric patients undergoing obesity treatment demonstrated that achieving obesity remission or good treatment response significantly reduced the risk of type 2 diabetes, dyslipidemia, hypertension, and premature mortality in young adulthood, according to research published in JAMA Pediatrics.

Conexiant

January 21, 2025

Pancreatic Enzymes and Autoantibodies Signal T1D Progression

Lipase and trypsinogen levels were differentially informative for distinguishing clinical groups in type 1 diabetes, researchers reported.

Conexiant

January 21, 2025

Crinecerfont Lowers Androgens, Glucocorticoids Safely

Crinecerfont reduced androstenedione by 197 ng/dL at week 4 and decreased glucocorticoid doses by 18% at week 28 in children with congenital adrenal hyperplasia, according to a NEJM study.

Conexiant

January 21, 2025

Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors

A recent study to be presented at the 2025 ASCO Gastrointestinal Cancers Symposium found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progressi...

The ASCO Post

January 16, 2025

Algorithm Improves Diagnosis of Uterine Lesions

"The preoperative 3-class diagnostic algorithm and risk class system can stratify women according to risk of malignancy."

Conexiant

January 16, 2025

Exercise Therapy as Candidate Anticancer Strategy

Lee Jones, PhD, Head of the Exercise Oncology Program at Memorial Sloan Kettering Cancer Center, shared findings from an early-phase clinical trial to determine the feasibility, safety, and tumor biol...

The ASCO Post

January 16, 2025

Study Questions Urokinase's Role in Minor Stroke Care

For minor stroke patients, urokinase showed no added benefit for 90-day outcomes but remained safe, TRUST trial reveals.

Conexiant

January 16, 2025

Bone Density Risks in Cancer Survivors

Discover how cancer treatments, lifestyle factors, and comorbidities contribute to long-term bone mineral density deficits in childhood cancer survivors.

Conexiant